Role of MBD3-SOX2 axis in residual myeloma following pomalidomide

Leukemia. 2021 Nov;35(11):3319-3323. doi: 10.1038/s41375-021-01145-0. Epub 2021 Feb 18.

Rakesh Verma¹, Andrew R Branagan², Mina L Xu^{3

4}, Richard A Flavell^{5

6}, Kavita M Dhodapkar^{7

8}, Madhav V Dhodapkar^{9

10}

¹ Department of Medicine, Yale University, New Haven, CT, USA. rakesh.verma@aya.yale.edu.
² Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Pathology, Yale University, New Haven, CT, USA.
⁴ Department of Laboratory Medicine, Yale University, New Haven, CT, USA.
⁵ Department of Immunobiology, Yale University, New Haven, CT, USA.
⁶ Howard Hughes Medical Institute, Yale University, New Haven, CT, USA.
⁷ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA.
⁸ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
⁹ Winship Cancer Institute, Emory University, Atlanta, GA, USA. madhav.v.dhodapkar@emory.edu.
¹⁰ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA. madhav.v.dhodapkar@emory.edu.

No abstract available

Publication types